Apply to trial NCT07710885

A few quick questions so the study team can decide if you might be a fit.

RecruitingPhase 3Drug trial

Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer

To compare overall survival (OS) of patients in Futibatinib and Zimberelimab in Combination with Gemcitabine plus Cisplatin versus Durvalumab or Pembrolizumab in Combination with Gemcitabine plus Cisplatin for patients with first-line advanced biliary tract cancer

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening